Good they actually have some understanding of the underlying mechanism. Also this is an oral drug! It reduced mortality risk by 92%: https://www.europeanpharmaceuticalreview.com/news/147167/pro...
But where I'm confused is why this drug in particular was studied, instead of an approved AR antagonist like bicalutamide or enzalutamide. Way easier to dispense those than some clinical trial drug, right? And is it important that the drug is a silent antagonist of AR rather than an inverse agonist?
Also, how does this affect women? Are we at less risk of mortality through this mechanism? My T levels are very low, but all of us have androgens and their receptors. Maybe TMPRSS2 gets transcribed even when T or DHT levels are low?
Generally with specialized papers we've found that it's best to link to the best third-party article and then have a link to the paper in the thread. Unfortunately the third party article often isn't great, but it's at least an easier place to get some context, and we can replace the URL when people point out a better one.
Asking as a layman:
Would that be a problem for patients who are unconscious or with breathing tubes?